Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

About the Linvoseltamab Clinical Development Program Linvoseltamab is an investigational BCMAxCD3 bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on MM cells with ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call. My name is Tawanda, and I will be your ...

Earnings Call Transcript January 30, 2025 Sanofi misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were $0.71. Thomas Larsen: Welcome to the Q4 and Full Year 2024 Conference Call ...

Obviously, Dupixent in COPD has a broader label ... Of course, any decision is subject to regulatory final active review. And then with respect to the label and monitoring, I think you'll see ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...

“We had received priority review from the FDA for that submission,” Reed said. “That’s the second time Spravato had received a priority review—the only antidepressant ever to do so—and Spravato is ...

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.

With less frequent dosing, Ebglyss is expected to compete fiercely with Dupixent, a treatment that racked up over $13 billion in sales last year. On Jan. 15, the FDA approved Lilly's Omvoh for the ...